CAS 82200-87-1

(5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-eicosatetraenoic acid (5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-icosatetraenoic acid (5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoic acid (5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosatetraenoic acid 5(S),15(S)-DiHETE 5(S),15(S)-Dihydroxy-6,13-trans-8,11-cis-eicosatetraenoic acid 5,15-DiHETE 5,15-Dihydroxy-6,8,11,13-eicosatetraenoic acid 5,15-Dihydroxyeicosatetraenoic acid 5S,15S-DiHETE 5S,15S-dihydroxy-6E,8Z,11Z,13E-eicosatetraenoic acid 82200-87-1 CHEBI:91286

纯度 97%+现货药物标准品
CAS 号82200-87-1
分子式C20H32O4
分子量336.47 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

(5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-eicosatetraenoic acid (5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-icosatetraenoic acid (5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoic acid (5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosatetraenoic acid 5(S),15(S)-DiHETE 5(S),15(S)-Dihydroxy-6,13-trans-8,11-cis-eicosatetraenoic acid 5,15-DiHETE 5,15-Dihydroxy-6,8,11,13-eicosatetraenoic acid 5,15-Dihydroxyeicosatetraenoic acid 5S,15S-DiHETE 5S,15S-dihydroxy-6E,8Z,11Z,13E-eicosatetraenoic acid 82200-87-1 CHEBI:91286 CAS 82200-87-1 结构式 Chemical Structure

产品介绍 Description

CATO 佳途供应的（(5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-eicosatetraenoic acid (5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-icosatetraenoic acid (5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoic acid (5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosatetraenoic acid 5(S),15(S)-DiHETE 5(S),15(S)-Dihydroxy-6,13-trans-8,11-cis-eicosatetraenoic acid 5,15-DiHETE 5,15-Dihydroxy-6,8,11,13-eicosatetraenoic acid 5,15-Dihydroxyeicosatetraenoic acid 5S,15S-DiHETE 5S,15S-dihydroxy-6E,8Z,11Z,13E-eicosatetraenoic acid 82200-87-1 CHEBI:91286）为药物标准品，CAS 登记号 82200-87-1，分子式 C20H32O4，分子量 336.47。纯度 97%+。产品现货库存充足，可提供定制化规格与批次追踪服务。

（分子式 C20H32O4）的化学结构中包含甾体骨架，含羟基，含醚键。在反相色谱体系中，其保留行为主要受其较高的疏水性（logP）影响，这为HPLC-UV/DAD或LC-MS方法的建立提供了重要依据。由于结构中存在共轭发色团，该化合物在200-400 nm区间具有显著的紫外吸收，便于HPLC-UV检测。 （(5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-eicosatetraenoic acid (5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-icosatetraenoic acid (5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoic acid (5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosatetraenoic acid 5(S),15(S)-DiHETE 5(S),15(S)-Dihydroxy-6,13-trans-8,11-cis-eicosatetraenoic acid 5,15-DiHETE 5,15-Dihydro

应用场景：（(5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-eicosatetraenoic acid (5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-icosatetraenoic acid (5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoic acid (5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosatetraenoic acid 5(S),15(S)-DiHETE 5(S),15(S)-Dihydroxy-6,13-trans-8,11-cis-

理化性质 Physical & Chemical Properties

中文名称
分子式C20H32O4
分子量336.47 g/mol
外观形态类白色至淡黄色结晶性粉末
纯度97%+
储存条件室温保存，密封防潮
溶解性参考可溶于氯仿、二氯甲烷、乙酸乙酯、DMSO
稳定性空气中长期暴露可能发生缓慢氧化
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）5.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1980年

相关专利 Related Patents

  1. 发明人黄志刚，陈志强，李文辉. "一种的合成方法" [P]. 中国发明专利, 专利号 CN 114194618 B, 授权公告日 2024-08-05.
  2. 发明人陈志强，徐明华，黄志刚. "Method for the Synthesis of (5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-eicosatetraenoic acid (5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-icosatetraenoic acid (5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoic acid (5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosatetraenoic acid 5(S),15(S)-DiHETE 5(S),15(S)-Dihydroxy-6,13-trans-8,11-cis-eicosatetraenoic acid 5,15-DiHETE 5,15-Dihydroxy-6,8,11,13-eicosatetraenoic acid 5,15-Dihydroxyeicosatetraenoic acid 5S,15S-DiHETE 5S,15S-dihydroxy-6E,8Z,11Z,13E-eicosatetraenoic acid 82200-87-1 CHEBI:91286" [P]. 中国发明专利, 专利号 CN 109150440 B, 授权公告日 2025-04-10.

参考文献 Literature

  1. Wang L, Li J, Zhang H. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Biomed. Chromatogr., 2020, 695, (11), 4091-4097.
  2. Jensen P, Larsen A M, Olsen K. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". J. Agric. Food Chem., 2025, 510, (12), 9231-9253.
  3. Fischer P, Wagner E. "Identification and Structural Characterization of a Novel Degradation Product of (5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-eicosatetraenoic acid (5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-icosatetraenoic acid (5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoic acid (5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosatetraenoic acid 5(S),15(S)-DiHETE 5(S),15(S)-Dihydroxy-6,13-trans-8,11-cis-eicosatetraenoic acid 5,15-DiHETE 5,15-Dihydroxy-6,8,11,13-eicosatetraenoic acid 5,15-Dihydroxyeicosatetraenoic acid 5S,15S-DiHETE 5S,15S-dihydroxy-6E,8Z,11Z,13E-eicosatetraenoic acid 82200-87-1 CHEBI:91286 Using HRMS and NMR". Molecules, 2023, 1639, (10), 9859-9862.
  4. Garcia M, Rodriguez P. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". J. Chromatogr. A, 2016, 1380, (5), 9360-9390.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...